TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Company Overview - TG Therapeutics (TGTX) is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings projected at $0.35 per share, reflecting a +133.3% change, and revenues expected to be $189.4 million, up 75.1% from the previous year [3]. Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 12.93% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for TG Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.43%, which complicates the prediction of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, TG Therapeutics had a significant earnings surprise, posting earnings of $2.43 per share against an expected $0.24, resulting in a surprise of +912.50% [13]. - Over the last four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - In comparison, Mirum Pharmaceuticals, Inc. (MIRM) is expected to post earnings of $0.02 per share for the same quarter, indicating a year-over-year change of +104.1%, with revenues projected at $141.27 million, up 42.1% [18]. - Mirum Pharmaceuticals has seen a significant upward revision of its EPS estimate by 50.9% over the last 30 days, resulting in an Earnings ESP of +675.00%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].